Veeva Announces Vault Site Connect to Automate Information Sharing in Clinical Trials
19.5.2020 10:00:00 EEST | Business Wire | Press release
2020 Veeva R&D Summit, Europe — Veeva Systems (NYSE: VEEV) today announced Veeva Vault Site Connect, a new application that connects sponsors and clinical research sites during trials. Vault Site Connect automates the flow of information between Vault Clinical applications used by sponsors and Veeva SiteVault, a compliant eISF application used by sites for source document management and remote monitoring. Now sponsors and sites can streamline information sharing for key trial processes, including feasibility, study document exchange, safety letter distribution, and subject status for faster study execution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200519005216/en/
Veeva Vault Site Connect automates the flow of information between clinical research sites and sponsors to speed trials.
“There is a significant opportunity to speed information exchange throughout the clinical trial process,” said Doug Schantz, member of SCRS leadership council and former head of U.S. site management and monitoring at AstraZeneca. “Veeva Vault Site Connect will transform how sponsors and sites work together and help get studies up and running much faster.”
Vault Site Connect seamlessly automates information flow across trial partners, processes, and systems. Sponsors can easily collect input from sites on study feasibility to spend less time coordinating surveys; accelerate document exchange and reconciliation between eTMF and eISF; quickly distribute safety letters to notify global sites and regulators of an adverse event; and get real-time information on the status of patients from enrollment through treatment – all with one application.
With Vault Site Connect, sponsors can improve site engagement by reducing the time and effort in exchanging clinical information. Now sites can focus less on administrative tasks and responding to information requests and more on execution and treating patients, improving overall study quality.
“Veeva Vault Site Connect will eliminate the many portal interfaces, manual handoffs, and multiple steps it takes to share data with sponsors during a trial,” said Tonya Yarbrough, director, Vanderbilt Institute for Clinical and Translational Research at Vanderbilt University Medical Center. “Now the industry can leverage the same innovative Veeva Vault technology to drive greater efficiency and productivity during trials.”
Vault Site Connect is part of the Veeva Clinical Network, a set of solutions that brings together sponsors, sites, and patients to accelerate clinical research. In addition to Vault Site Connect, Veeva today announced MyVeeva, a multichannel patient portal for virtual visits and patient-centric trials. Together with Veeva Vault Clinical Suite, Veeva is the first and only company providing solutions that help sponsors, sites, and patients share and view information during a clinical trial.
“Veeva aims to improve efficiency and collaboration across the clinical trial ecosystem,” said Rik Van Mol, vice president of strategy for Veeva Development Cloud. “With applications for sponsors, sites, and patients all part of the Veeva Clinical Network, we are providing a common way to connect and get real-time information throughout the course of a study.”
Vault Site Connect is planned for availability in August 2020. To learn how Site Connect automates information sharing in clinical trials, register for an upcoming webinar on 23 June at veeva.com/SiteConnectWebinar, as well as the online Veeva R&D Summit, 19-20 and 26 May, 2020.
Additional Information
For more on Veeva Vault Site Connect, visit: veeva.com/SiteConnectEU
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 850 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-K for the period ended January 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200519005216/en/
Contact information
Roger Villareal
Veeva Systems
925-264-8885
roger.villareal@veeva.com
Kiran May
Veeva Systems
+44-796-643-2912
kiran.may@veeva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
Galderma Tackles Menopause-related Skin Changes With Global Survey and Clinical Trial Inclusivity30.1.2026 08:00:00 EET | Press release
Galderma (SIX: GALD) has unveiled findings from a global survey of peri- and post-menopausal women from nine countries exploring the impact of menopause on the skin at the International Master Course on Aging Science (IMCAS) 2026 World Congress in Paris, France, from January 29-31, 2026. The survey found that over 50% of women learned about the effects of menopause on the skin by going through it themselves, with most finding out about it in their 40s.2 However, over 30% would have liked to learn about this in their 30s and over 50% are at best neutral or dissatisfied with their knowledge on the topic.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260129610958/en/ To address this knowledge gap, Galderma will leverage its expertise in dermatology to advance awareness, understanding, education, and treatment approaches for menopause-related skin changes. With around 85% of aesthetic patients being female, it is important to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
